Filing Flows › Health Care › Fennec Pharmaceuticals (FENC)
Fennec Pharmaceuticals (FENC) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Fennec Pharmaceuticals (FENC) Q2 2026 earnings results →
Q2 2026 Revenue up 85% year over year to $17.9M · 11¢ of every $1 of revenue kept as net profit · operating margin 9.7%
Fennec Pharmaceuticals made $17.9M in Q2 2026 (+85% Y/Y): PEDMARK product sales, net $17.2M, Other revenue $710K. Operating margin 9.7%, net earnings $2.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $17.9M in Q2 2026, up 85% year over year and up 18% from the previous quarter. PEDMARK product sales, net was the largest line at 96% of revenue. PEDMARK product sales, net added $7.5M year over year (up 78%), 91% of the total change.
Operating profit was $1.7M, a 9.7% margin (up 38.0 points year over year). Total costs grew 30% against revenue growth of 85%. The fastest-growing cost line was Sales & marketing (+123%). Net earnings were $2.0M. The effective tax rate was 2.1%.
Operating cash flow was $50K, 3% of net earnings. Non-cash charges added back $1.8M of share-based compensation. Working capital and other items used $3.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $17.9M | +85% | 9.7% | $2.0M | $50K |
| Q1 2026 | 10-Q | May 14, 2026 | $15.1M | +73% | -0.8% | $201K | $2.4M |
| Q4 2025 | 10-K | Mar 27, 2026 | $13.8M | +74% | -18.5% | −$4.8M | −$6.0M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $12.5M | +79% | -1.5% | −$637K | $1.5M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $9.7M | +33% | -28.3% | −$3.2M | −$3.7M |
| Q1 2025 | 10-Q | May 14, 2025 | $8.8M | -66% | -9.2% | −$1.2M | −$4.3M |
| Q4 2024 | 10-K | Mar 26, 2025 | $7.9M | -19% | -11.8% | −$2.0M | −$1.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Fennec Pharmaceuticals
You are urged to read this Annual Report on Form 10-K (“Annual Report”) in its entirety. “We,” “our,” “ours,” “us,” “Fennec,” or the “Company,” when used herein, refers to Fennec Pharmaceuticals Inc., a British Columbia corporation, and its wholly-owned subsidiary, Fennec Pharmaceuticals, Inc., a Delaware corporation. This Annual Report contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995. These include statements regarding our expectations, beliefs, plans or objectives for future operations and anticipated results of operations. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements.
In its own words, from its 10-K, filed Mar 27, 2026.
Fennec Pharmaceuticals against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +85% against the peers' median +29%. Operating margin: 9.7% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| FENC Fennec Pharmaceuticals | Q2 2026 | $17.9M | +85% | 9.7% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Fennec Pharmaceuticals 10-Q on SEC EDGAR · CIK 1211583 · Biological Products, (No Diagnostic Substances)
13F: who owns FENC and who is buying
More on FENC
- How Fennec Pharmaceuticals makes money: revenue by segment
- Fennec Pharmaceuticals next earnings date and what analysts expect
- Fennec Pharmaceuticals stock forecast, price target and fair value
- Who owns Fennec Pharmaceuticals stock: holders, funds and Congress trades
- Fennec Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results